We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency is recommending the first-ever malaria vaccine, GSK’s Mosquirix, as a protection for children ages six weeks to 17 months in sub-Saharan Africa. Read More
Global health experts are calling for at least $2 billion in seed money to spur vaccine development against diseases including Ebola, MERS, SARS, West Nile virus and Lyme disease. Read More
AstraZeneca’s investigational drug selumetinib has failed to meet its primary endpoint of progression free survival during a Phase 3 trial for a rare eye cancer. Read More
Roche will increase research and development efforts on two Alzheimer’s drugs that suffered setbacks in trials last year, as the race for a potential cure heats up. Read More
Eli Lilly and Biogen Wednesday reported back-to-back positive clinical trial results for their investigational Alzheimer’s disease drugs, heating up the race for an effective cure. Read More
Exelixis’ Cometriq improved patient outcomes in a pivotal Phase 3 trial for metastatic kidney cancer — signaling new life for the drug, which failed another study last fall. Read More
Bristol-Myers Squibb cut short a Phase 3 study of Opdivo for the treatment of renal cell carcinoma after the immunotherapy drug met its primary endpoint versus everolimus, the current standard treatment. Read More
Amgen is reporting a “clinically meaningful number” of patients showed complete remission in a Phase 2 study of its pricey drug to treat a rare strain of leukemia. Read More